Poolbeg Pharma - Update

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza.

Cathal Friel
Chairman
Jeremy Skillington
Chief Executive Officer

Company Events - POOLBEG PHARMA

Poolbeg - Year in Review 2023

Management Team, Poolbeg Pharma

Wed, 3 Jan 2024, 11:00am GMT

Poolbeg Pharma - Capital Markets Day

Jeremy Skillington, Chief Executive Officer

Wed, 30 Nov 2022, 10:00am GMT

Poolbeg Pharma - Interim results

Jeremy Skillington, Chief Executive Officer

Mon, 5 Sep 2022, 11:00pm BST

Poolbeg Pharma - Share Update

Cathal Friel, Chairman

Wed, 27 Apr 2022, 12:00pm BST

Poolbeg Pharma - Key POLB 002 European Patent Granted...

Jeremy Skillington, Chief Executive Officer

Thu, 14 Apr 2022, 5:00pm BST

Poolbeg Pharma - On Track to Commence LPS Human Challenge...

Jeremy Skillington, Chief Executive Officer

Fri, 1 Apr 2022, 7:05am BST

Poolbeg Pharma - AI Analysis of Human Challenge Data...

Jeremy Skillington, Chief Executive Officer

Fri, 25 Mar 2022, 7:05am GMT

Poolbeg Pharma - Results to December 31st

Management Team, Poolbeg Pharma

Thu, 3 Mar 2022, 9:00am GMT

Poolbeg Pharma - Artificial Intelligence deal signed with...

Liam Tremble, PhD, Project Manager

Thu, 24 Feb 2022, 7:05am GMT

Poolbeg Pharma - Licence Signed for Development of Oral...

Jeremy Skillington, Chief Executive Officer

Mon, 31 Jan 2022, 7:05am GMT

Poolbeg Pharma plc - Agreement signed for MelioVac with...

Cathal Friel, Chairman

Mon, 6 Dec 2021, 7:05am GMT

Poolbeg Pharma - Interview with Elaine Sullivan...

Elaine Sullivan, Poolbeg Scientific Advisory Board

Wed, 1 Dec 2021, 7:00am GMT

Poolbeg Pharma - Update

Cathal Friel, Chairman

Thu, 18 Nov 2021, 5:11pm GMT

Poolbeg Pharma - POLB 001

Jeremy Skillington, Chief Executive Officer

Tue, 20 Jul 2021, 9:00am BST